Concurrent 7C: Monitoring WHO HCV elimination targets – UK progress & implications for other settings
Tracks
Track 3
| Friday, October 17, 2025 |
| 2:00 PM - 3:30 PM |
| Hall C |
Details
We first outline WHO approach to measuring HCV elimination targets - in particular on how to assess progress in countries where it is important to measure HCV incidence among People Who Inject Drugs. We summarise approach in UK and evidence of targets that have already been met. Then we synthesise evidence from multiple studies in UK and globally evaluating impact of HCV treatment scale-up and progress towards WHO HCV elimination targets.
Speaker
Dr Sema Mandal
Medical Consultant Epidemiologist
UK Health Security Agency
Introduction
2:00 PM - 2:10 PMBiography
Dr Adelina Artenie
Assistant professor
University of Montreal
Global modelling of HCV incidence
2:10 PM - 2:25 PMBiography
Professor Sharon Hutchinson
Professor Of Epidemiology And Population Health
Glasgow Caledonian University
Public Health Surveillance & Statistical modelling of chronic HCV in PWID
2:25 PM - 2:40 PMBiography
Sharon Hutchinson is a Professor of Epidemiology and Population Health at Glasgow Caledonian University and an Honorary Consultant at Public Health Scotland. She leads a programme of surveillance and research on hepatitis C and other blood-borne viruses. Her research has provided the key evidence to inform Scotland’s response to hepatitis C.
Professor Peter Vickerman
Professor Of Infectious Disease Modelling
University Of Bristol
Dynamic modelling of HCV Treatment as Prevention (TasP) in UK settings
2:40 PM - 2:55 PMBiography
Prof Matthew Hickman
Professor in Public Health and Epidemiology
Professor in Public Health and Epidemiology
Cost-effectiveness of HCV treatment scale-up
2:55 PM - 3:10 PMBiography
INHSU 2025
Panel discussion: Implications for other countries
3:10 PM - 3:30 PMBiography
Chairperson
Sema Mandal
Medical Consultant Epidemiologist
UK Health Security Agency
